Edition:
United States

Karo Pharma AB (KARO.ST)

KARO.ST on Stockholm Stock Exchange

32.55SEK
5:50am EDT
Change (% chg)

0.70kr (+2.20%)
Prev Close
31.85kr
Open
31.80kr
Day's High
32.80kr
Day's Low
31.50kr
Volume
272,167
Avg. Vol
776,172
52-wk High
38.37kr
52-wk Low
25.25kr

Chart for

About

Karo Pharma AB, formerly known as Karo Bio AB, is a Sweden-based biopharmaceutical company engaged in the research and development of drugs based on the nuclear receptors. The Company’s pipeline comprises three projects: Estrogen Receptor Beta (ERbeta) cancer, a platform, which focuses on the development of ERbeta in cancer... (more)

Overall

Beta: 0.90
Market Cap(Mil.): kr5,234.00
Shares Outstanding(Mil.): 164.33
Dividend: 0.28
Yield (%): 0.89

Financials

  KARO.ST Industry Sector
P/E (TTM): 7.94 103.50 32.14
EPS (TTM): 4.01 -- --
ROI: 15.02 1.52 12.66
ROE: 23.35 0.25 14.84

BRIEF-Karo Pharma Determines Terms For Rights Issue

* THE TERMS FOR KARO PHARMA'S RIGHTS ISSUE HAVE BEEN DETERMINED

Apr 30 2018

BRIEF-Karo Pharma Q1 EBITDA rose to SEK 89 mln

* KARO PHARMA DOUBLES SALES AND EARNINGS IN THE FIRST QUARTER

Apr 26 2018

BRIEF-Karo Pharma: Board Of Directors Resolves On Fully Guaranteed Rights Issue

* THE BOARD OF DIRECTORS OF KARO PHARMA HAS RESOLVED ON A FULLY GUARANTEED RIGHTS ISSUE SUBJECT TO APPROVAL BY THE ANNUAL GENERAL MEETING

Apr 04 2018

BRIEF-Karo Pharma Intends To Propose Dividend Of SEK 0.30 Per Share

* INTENDS TO PROPOSE DIVIDEND OF SEK 0.30 PER SHARE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Apr 03 2018

Earnings vs. Estimates